News

Published on 17 Jun 2022 on MarketWatch

Acadia Pharmaceuticals stock halted for FDA panel to review treatment for hallucinations stemming...


Article preview image

Acadia Pharmaceuticals Inc. said Friday its stock will be halted from trading Friday as a U.S. Food and Drug Administration panel meets virtually to discuss a new drug application for a treatment for hallucinations and delusions associated with Alzheimer's disease psychosis. The FDA's Psychopharmacologic Drugs Advisory Committee will review Acadia's Nuplazid at a meeting scheduled for 8:45 a.m. Eastern. About six million people living in the U.S. have Alzheimer's disease, according to the Alzheimer's Association and about 30% of those suffer from psychosis. Acadia shares have fallen 16% in the year to date, while the S&P 500 has fallen 23%.

NASDAQ.ACAD price evolution
NYSE.STEM price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Stem Inc. downgraded by Goldman Sachs to neutral By Investing.com

On Friday, Goldman Sachs (NYSE:GS) adjusted its stance on Stem Inc. (NYSE:STEM), a smart energy...

Investing.com 22 Mar 2024

Stem Inc. director David Buzby buys $61k in company shares By Investing.com

Stem Inc. director David Buzby buys $61k in company shares

Investing.com 20 Mar 2024

Stem Inc. chief people officer buys $44.2k in company stock By Investing.com

s (NYSE:STEM) Chief People Officer, Homenock Kim, acquired additional shares of the company. On...

Investing.com 18 Mar 2024

Stem, Inc. (NYSE:STEM) Q4 2023 Earnings Call Transcript

Stem, Inc. (NYSE:STEM) Q4 2023 Earnings Call Transcript February 28, 2024 Stem, Inc. misses on ea...

Insider Monkey via Yahoo Finance 29 Feb 2024

Stem Inc. share price target cut by BMO Capital, lays out software strategy By Investing.com

Stem Inc. share price target cut by BMO Capital, lays out software strategy

Investing.com 29 Feb 2024

Earnings call: Stem Inc. achieves positive adjusted EBITDA in Q4 By Investing.com

Stem Inc. (NYSE:STEM), a leader in energy storage and solar solutions, has reported a significant...

Investing.com 29 Feb 2024

Stem Inc. mixed Q4 results prompt Roth/MKM to cut stock price target to $2.70 By Investing.com

Stem Inc. mixed Q4 results prompt Roth/MKM to cut stock price target to $2.70

Investing.com 29 Feb 2024

Earnings call: Stem Inc. achieves positive adjusted EBITDA in Q4 By Investing.com

Stem Inc. (NYSE:STEM), a leader in energy storage and solar solutions, has reported a significant...

Investing.com 29 Feb 2024

Stem Inc. share price target cut by BMO Capital, lays out software strategy

Stem Inc. share price target cut by BMO Capital, lays out software strategy

Investing.com 29 Feb 2024

Shoals Technologies Posts Weak Q4 Results, Joins Butterfly Network, Schrödinger And Other Big Stocks...

U.S. stock futures were lower this morning, with the Dow futures trading lower by over 100 points...

Benzinga 29 Feb 2024